A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Mau-Soerensen, Morten
  • Razak, Albiruni RA
  • Shields, Anthony Frank
  • Gabrail, Nashat Y
  • Gerecitano, John F
  • Shacham, Sharon
  • Lassen, Ulrik Niels
  • Rashal, Tami
  • Cooksey, Jennifer
  • Landesman, Yosef
  • Pond, Gregory
  • Oza, Amit M
  • Kauffman, Michael
  • Siu, Lillian L
  • Bedard, Philippe L
  • Mahaseth, Hemchandra
  • Mirza, Mansoor Raza
  • Mahipal, Amit

publication date

  • May 20, 2014